References
1. Characterization of the interaction of ingenol 3-angelate with protein kinase C: N. Kedei, et al.; Cancer Res. 64, 3243 (2004)|2. Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells: S.K. Gillespie, et al.; Mol. Cancer Ther. 3, 1651 (2004)|3. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC: P. Hampson, et al.; Blood 106, 1362 (2005)|4. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate: J.M. Challacombe, et al.; J. Immunol. 177, 8123 (2006)|5. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner: P. Hampson, et al.; Cancer Immunol. Immunother. 57, 1241 (2008)|6. Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies: T.T. Le, et al.; Vaccine 27, 3053 (2009)|7. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis: L. Anderson, et al.; J. Am. Acad. Dermatol. 60, 934 (2009)|8. Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta: W.Y. Lee, et al.; JBC 285, 23889 (2010)USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
